IRVINE, CA / ACCESSWIRE / June 7, 2016 / Khang & Khang LLP (the “Firm”) announces that a class action lawsuit has been filed against First NBC Bank Holding Company (“First NBC” or the “Company”) (Nasdaq: FNBC). Investors who purchased or otherwise acquired shares between May 10, 2013 and April 8, 2016, inclusive (the “Class Period”), are encouraged to contact the Firm prior to the July 5, 2016, lead
plaintiff motion deadline.

If you purchased shares of First NBC during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by email at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

According to the complaint, the Company made materially false and misleading statements to investors and/or failed to disclose that: (1) the Company had not properly accounted for certain of its tax credit entities; and (2) the carrying value of its investments in tax credits on its books was overstated.

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by email at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

KHANG & KHANG LLP
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 440877

TORONTO, ON / ACCESSWIRE / June 7, 2016 / The Canadian Bioceutical Corporation (“BCC” or the “Corporation“) (TSX VENTURE: BCC.V) (OTC: CBICF) is pleased to announce that it is has closed the second and final tranche of its private placement offering of convertible debentures (“Debentures“) to arm’s length investors announced on April 4, 2016. The Corporation received aggregate loan gross proceeds of £60,000 ($110,277.75). No fees or commissions were paid as part of the financing. On closing the second tranche, BCC received an additional £40,000 ($37,536.00) of loan gross proceeds.

Proceeds of this financing will be used to fund the initial costs of the acquisition of a U.S.-based medical marijuana enterprise as well as for the opportunities in other US States that are presented as a result of the proposed acquisition further to the Company’s press release dated January 25, 2016.

The Debentures are unsecured and pay 6% interest per annum, calculated and paid annually and mature three years from the date of issuance. The Debentures are convertible into units of the Company (the “Units“) at the option of the subscriber at any time until maturity at a price of either (a) $0.35 per Share; or (b) on the same terms and conditions (including (without limitation) at the same price per share) as those applicable to any sale of capital stock to any other investor at any time between the date of issuance and the date the subscriber exercises its right of conversion, but, in any case, not less than $0.35 (the “Conversion Price“).

Each Unit is comprised of one common share in the capital of the Company (a “Common Share“) and one common share purchase warrant of the Corporation (a “Warrant“). Each Warrant entitles the holder thereof to purchase one Common Share (a “Warrant Share“) for thirty-six (36) months following the closing date at either (at the option of the holder): (a) $0.65 per Warrant Share; or (b) on the same terms and conditions (including (without limitation) at the same price per share) as those applicable to any sale of capital stock to any other investor at any time between the date of issuance of the debenture and the date of the holder exercising its right of conversion, but, in any case, not less than $0.65 (the “Warrant Share Price”).

The Debentures, and any common shares issuable upon conversion thereof, will be subject to a four-month hold period in accordance with applicable securities laws. The offering is subject to the final approval of the TSX Venture Exchange.

About The Canadian Bioceutical Corporation

BCC, formerly Allegiance Equity Corporation, is an Ontario corporation that, for over two decades has been developing unique standardized mass-market nutraceutical products for the treatment of common ailments where present pharmaceutical treatments and over-the-counter products fail to meet the needs of patients. BCC has targeted markets having clearly identified product deficiencies and dissatisfied consumers afflicted with a variety of medical conditions. BCC obtains regulatory approval and patents for these unique compounds and formulations and may produce and distribute or license its products for royalty revenues.

BCC’s principal brands are CinG-X™, Reliéva™ and FertaMax™. The company, through its subsidiary, BioCannabis Products Ltd., and subsequent to receiving its MMPR license from Health Canada and the potential revision of these regulations, intends to develop and market a series of new cannabis-based branded medicinal products to address this rapidly-evolving market.

CSA Investor Caution

Investors should be aware that companies cannot legally conduct a medical marijuana business without a license from Health Canada and that there is significant time and cost required to obtain such a license. As a publicly-traded company publicizing its intention to enter the medical marijuana industry, BCC urges potential investors in any company in this sector, to become familiar with the required resources and the related risks, costs implications and time required before a company will be able to begin licensed operations. There is no assurance that any company announcing its intent to enter the medical marijuana industry will be successful in obtaining a license or in creating shareholder value.

Cautionary Statement Regarding Forward-Looking Information

This news release includes certain “forward-looking statements” under applicable Canadian securities legislation that are not historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release include, but are not limited to, the Transaction and BCC’s objectives and intentions. Forward-looking statements are necessarily based on a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic and social uncertainties; litigation, legislative, environmental and other judicial, regulatory, political and competitive developments; delay or failure to receive board, shareholder or regulatory approvals; those additional risks set out in BCC’s public documents filed on SEDAR at www.sedar.com; and other matters discussed in this news release. Although BCC believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, BCC disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the Policies of the Exchange) accepts responsibility of the adequacy or accuracy of this release.

For further information please contact:

Scott Boyes, President and CEO
scott@canadianbioceutical.com
(416) 840-4703

SOURCE: The Canadian Bioceutical Corporation

ReleaseID: 440864

LITTLE FALLS, NJ / ACCESSWIRE / June 7, 2016 / Cantel Medical Corp. (NYSE: CMN) will host a conference call and live webcast to discuss the results of the third quarter 2016, to be held Wednesday, June 8, 2016 at 11:00 AM Eastern Time.

To participate in this event, dial 877-407-8033 domestically or 201-689-8033 internationally, approximately 5 to 10 minutes before the beginning of the call. Additionally, you can listen to the event online at www.investorcalendar.com/IC/CEPage.asp?ID=175058 as well as via the Cantel website (www.cantelmedical.com).

If you are unable to participate during the live webcast, the event archive will be available at www.investorcalendar.com or www.cantelmedical.com.

You may access the teleconference replay by dialing 877-660-6853, referencing conference ID # 13638600. The replay will be available beginning approximately 2 hours after the completion of the live event, ending at midnight Eastern on August 8, 2016.

About Cantel Medical Corp.

Cantel Medical is a leading global company dedicated to delivering innovative infection prevention and control products and services for patients, caregivers, and other healthcare providers which improve outcomes, enhance safety and help save lives. Our products include specialized medical device reprocessing systems for endoscopy and renal dialysis, advanced water purification equipment, sterilants, disinfectants and cleaners, sterility assurance monitoring products for hospitals and dental clinics, disposable infection control products primarily for dental and GI endoscopy markets, dialysate concentrates and hollow fiber membrane filtration and separation products. Additionally, we provide technical service for our products. For further information, visit the Cantel website at www.cantelmedical.com.

SOURCE: Investor Calendar

ReleaseID: 440794

NEW YORK, NY / ACCESSWIRE / June 7, 2016 / Pomerantz LLP is investigating claims on behalf of investors of Perrigo Company plc (“Perrigo” or the “Company”) (NYSE: PRGO). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

[Click here to join a class action]

The investigation concerns whether Perrigo and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On April 8, 2015, Mylan N.V. (“Mylan”) approached the Perrigo Board of Directors with an offer to purchase the Company for $205 per share, representing a nearly 30% premium to Perrigo’s total market capitalization. On news of Mylan’s offer, the price of Perrigo stock climbed as high as $215 per share in intraday trading on April 8, 2015.

However, beginning on April 21, 2015, and continuing throughout the Class Period, Perrigo publicly rejected Mylan’s offer and told investors that the offer substantially undervalued Perrigo and its growth prospects, and that the offer did not take into account the full benefits of the Company’s acquisition of Omega Pharma N.V. (“Omega”). Even though Mylan subsequently raised its offer to approximately $235 per share, over the next six months, Perrigo continued to engage in a public campaign to convince shareholders to reject Mylan’s proposal.

On November 13, 2015, the majority of the Company’s shareholders declined to tender their shares, making the tender offer a failure. Subsequently, several disclosures by the Company between February 17 and May 12, 2016–including weaker-than-expected fourth-quarter 2015 financial and operating results, the departure of Perrigo’s longtime Chief Executive Officer Joseph C. Papa, and a $467 million impairment charge relating to the Omega acquisition–saw the Company’s stock price fall from $145.17 to $98.04 in a series of sharp drops.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 440869

VANCOUVER, BC / ACCESSWIRE / June 7, 2016 / Far Resources Ltd. (CSE: FAT) (“Far Resources” or “the Company“) wishes to announce that subsequent to a review of data acquired during a field visit to the Zoro1 claim (the “Claim”) and a review of historical 1956 assessment files, the Company is unclear as to the exact locations and grades of some of the lithium-bearing dykes present on the Claim. The presence of the main dyke where the majority of diamond drilling was undertaken has been established on the Claim. This dyke was tested by a total of 3048 metres with a calculated tonnage of 1.8 million tonnes at a grade of 1.4% Li(2)O to a depth of 305 metres was established. A review of all historic field information is underway in an attempt to clarify the number of dykes on the property.

Accordingly, estimates of grade and intercept width is historical and was calculated prior to the implementation of National Instrument 43-101 Standards of Disclosure of for Mineral Projects (“NI 43-101”) using historical terminology and is not meant to be interpreted as a current estimate as defined in sections 1.2 and 1.3 of NI 43-101. The grades are presented solely to provide a historical frame of reference and as a guide to future exploration. Although believed to be reliable, no “qualified person” as defined in NI 43-101 has done sufficient work to classify the historical estimate as a current mineral resource or mineral reserve. Accordingly, the Company is not treating the historical estimate as a current mineral resource or mineral reserve and it should not be relied upon. Further exploration including new diamond drilling will be required to assess and verify the historical estimate as current mineral resources or mineral reserves.

The scientific and technical information regarding the Zoro1 Property contained in this news release has been approved by Mark Fedikow, P.Geo., a consultant of Far Resources and a “qualified person” as defined in NI 43-101.

About the Company

Far Resources Ltd. is an exploration company, publicly traded on the Canadian Securities Exchange under the symbol FAT, focused on the identification and development of high potential mineral opportunities in stable jurisdictions.

ON BEHALF OF THE BOARD OF DIRECTORS OF
FAR RESOURCES LTD.

“Keith C. Anderson”
President
604-805-5053

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

This news release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected. All of the forward-looking statements made in this news release and the accompanying graphic links are qualified by these cautionary statements and those in our continuous disclosure filings available on SEDAR at www.sedar.com. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

SOURCE: Far Resources Ltd.

ReleaseID: 440868

LOS ANGELES, CA / ACCESSWIRE / June 7, 2016 / Lundin Law PC announces a class action lawsuit has been filed against PJT Partners Inc. (“PJT Partners” or the “Company”) (NYSE: PJT) concerning possible violations of federal securities laws between November 12, 2015 and March 28, 2016. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the July 14, 2016, lead plaintiff motion deadline.

To participate in this class action lawsuit, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via e-mail at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the complaint, the Company failed to disclose that: (1) the Company’s compliance procedures were insufficient; and (2) as a result of the Company’s insufficient internal controls, a managing partner at Park Hill Group defrauded investors of more than $95 million.

Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlaw.com

SOURCE: Lundin Law PC

ReleaseID: 440867